Rigel Pharmaceuticals Accounts Payables 2011-2025 | RIGL

Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.

Main types of accounts payable

Type of liability	Example
To suppliers and contractors	Goods received but not yet paid for
Taxes and fees	VAT, income tax, etc., not paid on time
Salaries	Employee wages not paid
To budgets	Insurance contributions to funds not paid
To founders	Founders provided borrowed funds
To banks	Overdue loan payments
Other	Fines, penalties, forfeits, customer prepayments, etc.

Impact on the company's financial performance

Liquidity and solvency
Accounts payable are part of short-term liabilities, so they affect liquidity ratios
Financial stability
The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence
Capital turnover
Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals)
Risks and reputation
Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated

Annual Accounts Payables Rigel Pharmaceuticals

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
3.34 M	7.14 M	22.5 M	3.8 M	3.71 M	4.15 M	6.39 M	2.64 M	5.56 M	2.76 M	1.61 M	3.9 M	1.7 M	1.56 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
22.5 M	1.56 M	5.05 M

Quarterly Accounts Payables Rigel Pharmaceuticals

2025-Q3	2025-Q2	2025-Q1	2024-Q3	2024-Q2	2024-Q1	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
3.85 M	7.29 M	3.95 M	3.82 M	6.13 M	9.28 M	8 M	5.24 M	6.3 M	22.5 M	2.72 M	-	4.61 M	3.8 M	3.14 M	1.69 M	5.1 M	3.71 M	3.71 M	3.71 M	3.71 M	4.15 M	4.15 M	4.15 M	4.15 M	6.39 M	6.39 M	6.39 M	6.39 M	2.64 M	2.64 M	2.64 M	2.64 M	5.56 M	5.56 M	5.56 M	5.56 M	2.76 M	2.76 M	2.76 M	2.76 M	1.61 M	1.61 M	1.61 M	1.61 M	3.9 M	3.9 M	3.9 M	3.9 M	1.7 M	1.7 M	1.7 M	1.7 M	1.56 M	1.56 M	1.56 M	1.56 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
22.5 M	1.56 M	4.17 M

Accounts Payables of other stocks in the Biotechnology industry

Issuer	Accounts Payables	Price	% 24h	Market Cap	Country
Arbutus Biopharma Corporation ABUS	3.22 M	$ 4.93	4.78 %	$ 818 M	Canada
Aclaris Therapeutics ACRS	4.69 M	$ 3.2	-1.69 %	$ 247 M	USA
AlloVir ALVR	247 K	-	4.14 %	$ 49.1 M	USA
BioVie BIVI	2.2 M	$ 1.42	-1.85 %	$ 2.1 M	USA
ARCA biopharma ABIO	3.46 M	-	1052.0 %	$ 415 M	USA
Acasti Pharma ACST	601 K	-	4.01 %	$ 150 M	Canada
Adaptimmune Therapeutics plc ADAP	8.13 M	-	-15.15 %	$ 60.3 M	Britain
Aeglea BioTherapeutics AGLE	677 K	-	-	$ 1.01 B	USA
Albireo Pharma ALBO	6.52 M	-	-0.23 %	$ 916 M	USA
Alpine Immune Sciences ALPN	4.29 M	-	-	$ 2.17 B	USA
Ampio Pharmaceuticals AMPE	750 K	-	-11.43 %	$ 502 K	USA
Amphastar Pharmaceuticals AMPH	30.5 M	$ 26.45	4.67 %	$ 1.28 B	USA
Applied Molecular Transport AMTI	1.58 M	-	-	$ 10.1 M	USA
Anika Therapeutics ANIK	9.86 M	$ 9.6	0.37 %	$ 141 M	USA
Can-Fite BioPharma Ltd. CANF	561 K	$ 0.26	-6.98 %	$ 566 M	Israel
Catalyst Biosciences CBIO	355 K	$ 12.98	-7.91 %	$ 854 M	USA
Arena Pharmaceuticals ARNA	13.3 M	-	-6.81 %	$ 3.04 B	USA
Athersys ATHX	9.16 M	-	3.77 %	$ 22.4 M	USA
Acer Therapeutics ACER	3.81 M	-	2.71 %	$ 14 M	USA
Avenue Therapeutics ATXI	155 K	-	-52.27 %	$ 4.45 M	USA
AVROBIO AVRO	27 K	-	1083.1 %	$ 745 M	USA
Axon Enterprise AXON	72 M	$ 548.58	-2.78 %	$ 41.6 B	USA
Ayala Pharmaceuticals AYLA	4.08 M	-	-	$ 7.46 M	Israel
Aytu BioScience AYTU	10.6 M	$ 2.37	2.83 %	$ 14.9 M	USA
Celldex Therapeutics CLDX	3.26 M	$ 27.09	-1.53 %	$ 1.74 M	USA
Acorda Therapeutics ACOR	13.4 M	-	-24.86 %	$ 820 K	USA
Brickell Biotech BBI	406 K	-	-5.38 %	$ 6.06 M	USA
BeiGene, Ltd. BGNE	405 M	-	0.49 %	$ 251 B	Cayman-islands
Biohaven Pharmaceutical Holding Company Ltd. BHVN	51.7 M	$ 11.33	-1.78 %	$ 733 M	USA
Biogen BIIB	424 M	$ 175.2	0.63 %	$ 25.5 B	USA
Abeona Therapeutics ABEO	1.86 M	$ 5.07	-5.5 %	$ 108 M	USA
Corcept Therapeutics Incorporated CORT	15.4 M	$ 87.67	-0.36 %	$ 9.05 B	USA
ADiTx Therapeutics ADTX	10.2 M	$ 1.43	-36.18 %	$ 18.8 K	USA
Cellectar Biosciences CLRB	5.62 M	$ 3.28	-9.39 %	$ 40.1 M	USA
Bellicum Pharmaceuticals BLCM	486 K	-	-9.72 %	$ 5.89 M	USA
Berkeley Lights BLI	10.1 M	-	-7.31 %	$ 87 M	USA
Advaxis ADXS	6.08 M	-	-9.65 %	$ 45.9 M	USA
Catalyst Pharmaceuticals CPRX	16.6 M	$ 24.29	2.84 %	$ 2.88 B	USA